Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US

MT Newswires Live2025-03-06

Scienture (SCNX) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US.

Financial details weren't disclosed.

Under the terms of the agreement, Kindeva Drug Delivery, the parent company of Summit Biosciences, will manufacture and supply Rezenopy nasal spray 10mg, while Scienture will retain ownership of the New Drug Application for Rezenopy and oversee US sales, marketing, and distribution.

Shares of Scienture jumped more than 31% in recent Thursday trading.

Price: 2.83, Change: +0.62, Percent Change: +28.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2517610151?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517610151","market":"hk","top_or_hot":-1,"title":"Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US","media":"MT Newswires Live","content":"<html><body><p> Scienture (SCNX) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US.</p><p>Financial details weren't disclosed.</p><p>Under the terms of the agreement, Kindeva Drug Delivery, the parent company of Summit Biosciences, will manufacture and supply Rezenopy nasal spray 10mg, while Scienture will retain ownership of the New Drug Application for Rezenopy and oversee US sales, marketing, and distribution.</p><p>Shares of Scienture jumped more than 31% in recent Thursday trading.</p><p>Price: 2.83, Change: +0.62, Percent Change: +28.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-06 23:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Scienture (SCNX) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US.</p><p>Financial details weren't disclosed.</p><p>Under the terms of the agreement, Kindeva Drug Delivery, the parent company of Summit Biosciences, will manufacture and supply Rezenopy nasal spray 10mg, while Scienture will retain ownership of the New Drug Application for Rezenopy and oversee US sales, marketing, and distribution.</p><p>Shares of Scienture jumped more than 31% in recent Thursday trading.</p><p>Price: 2.83, Change: +0.62, Percent Change: +28.05</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517610151","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517610151","pubTimestamp":1741275457,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Scienture (SCNX) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","SCNX":"Scienture Holdings, Inc.","BK4167":"医疗保健技术","SMMF":"Summit Financial Group"},"translate_title":"Scienture Unit与Summit Biosciences合作在美国推出用于阿片类药物过量治疗的纳洛酮喷雾剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMF":1,"SCNX":0.9},"content_text":"Scienture (SCNX) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US.Financial details weren't disclosed.Under the terms of the agreement, Kindeva Drug Delivery, the parent company of Summit Biosciences, will manufacture and supply Rezenopy nasal spray 10mg, while Scienture will retain ownership of the New Drug Application for Rezenopy and oversee US sales, marketing, and distribution.Shares of Scienture jumped more than 31% in recent Thursday trading.Price: 2.83, Change: +0.62, Percent Change: +28.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517610151","isCrawlerRequest":true}